Trial Search Results

A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer

The main purpose of this study is to compare progression-free survival for women with hormone receptor positive (HR+), human epidermal growth factor receptor (HER2) negative advanced breast cancer receiving either abemaciclib+fulvestrant or fulvestrant alone. Participants will be randomized to abemaciclib or placebo in a 2:1 ratio. The study will last about 9 months for each participant.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Eli Lilly and Company

Intervention(s):

  • Drug: Abemaciclib
  • Drug: Fulvestrant
  • Drug: Placebo

Phase:

Phase 3

Eligibility


Inclusion Criteria

   - Have a diagnosis of HR+, HER2- breast cancer

   - Have locally advanced disease not amenable to curative treatment by surgery or
   metastatic disease. In addition, participants must fulfill 1 of the following
   criteria:

      - relapsed with radiologic evidence of progression while receiving neoadjuvant or
      adjuvant endocrine therapy, with no subsequent endocrine therapy received
      following progression

      - relapsed with radiologic evidence of progression within 1 year from completion of
      adjuvant endocrine therapy, with no subsequent endocrine therapy received
      following progression

      - relapsed with radiologic evidence of progression more than 1 year from completion
      of adjuvant endocrine therapy and then subsequently relapsed with radiologic
      evidence of progression after receiving treatment with either an antiestrogen or
      an aromatase inhibitor as first-line endocrine therapy for metastatic disease.
      Participants may not have received more than 1 line of endocrine therapy or any
      prior chemotherapy for metastatic disease

      - presented de novo with metastatic disease and then relapsed with radiologic
      evidence of progression after receiving treatment with either an antiestrogen or
      an aromatase inhibitor as first line endocrine therapy for metastatic disease.
      Participants may not have received more than 1 line of endocrine therapy or any
      prior chemotherapy for metastatic disease

   - Have postmenopausal status due to either surgical/natural menopause or ovarian
   suppression (initiated at least 28 days prior to Day 1 of Cycle 1) with a
   gonadotropin-releasing hormone (GnRH) agonist such as goserelin

   - Have a negative serum pregnancy test at baseline (within 14 days prior to
   randomization) and agree to use medically approved precautions to prevent pregnancy
   during the study and for 12 weeks following the last dose of abemaciclib if
   postmenopausal status is due to ovarian suppression with a GnRH agonist

   - Have either measurable disease or nonmeasurable bone only disease

   - Have a performance status ≤1 on the ECOG scale

   - Have discontinued previous therapies for cancer (including specifically, aromatase
   inhibitors, anti-estrogens, chemotherapy, radiotherapy, and immunotherapy) for at
   least 21 days for myelosuppressive agents or 14 days for nonmyelosuppressive agents
   prior to receiving study drug, and recovered from the acute effects of therapy (until
   the toxicity resolves to either baseline or at least Grade 1) except for residual
   alopecia or peripheral neuropathy

Exclusion Criteria

   - Are currently receiving an investigational drug in a clinical trial or participating
   in any other type of medical research judged not to be scientifically or medically
   compatible with this study

   - Have visceral crisis, lymphangitic spread, or leptomeningeal carcinomatosis visceral
   crisis is not the mere presence of visceral metastases but implies severe organ
   dysfunction as assessed by symptoms and signs, laboratory studies, and rapid
   progression of the disease

   - Have clinical evidence or history of central nervous system metastasis

   - Have received prior treatment with chemotherapy (except for neoadjuvant/ adjuvant
   chemotherapy), fulvestrant, everolimus, or any CDK4/6 inhibitor

   - Have received treatment with a drug that has not received regulatory approval for any
   indication within 14 or 21 days prior to randomization of study drug for a
   nonmyelosuppressive or myelosuppressive agent, respectively

   - Have received recent (within 28 days prior to randomization) yellow fever vaccination

   - Have had major surgery within 14 days prior to randomization of study drug to allow
   for post-operative healing of the surgical wound and site(s)

   - Have a personal history within the last 12 months of any of the following conditions:
   syncope of cardiovascular etiology, ventricular tachycardia, ventricular fibrillation,
   or sudden cardiac arrest

   - Have inflammatory breast cancer or a history of any other cancer (except nonmelanoma
   skin cancer or carcinoma in-situ of the cervix), unless in complete remission with no
   therapy for a minimum of 3 years

   - Have received an autologous or allogeneic stem-cell transplant

   - Have active bacterial or fungal infection, or detectable viral infection

   - Have initiated bisphosphonates or approved Receptor activator of nuclear factor
   kappa-B (RANK) ligand targeted agents <7 days prior to randomization

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study

Female

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting